The SSc/(+) sicca group did not differ significantly from the ACA+/SS group in the prevalence of anti-Ro/SS-A and anti-La/SS-B autoantibodies, while SSc/(-) sicca patients displayed neither anti-Ro/SS-A nor anti-La/SS-B reactivity in their sera. This evidence concerns the gene SSB and synovial sarcoma.